Highest-materiality recent filing
USANA Q2 net loss $21.4M on $223M sales; cuts FY guidance, records $29M Hiya impairment
Net loss of $21.4M (diluted EPS $(1.16)) vs net income of $9.7M ($0.52) a year ago; adjusted EPS $(0.07) vs $0.74.
Each of eight director nominees received over 13.6M votes for; no nominee had material withheld count.
USANA Q1 2026 EPS down 16% YoY to $0.41; reaffirms FY guidance
Net sales $250M flat YoY; net earnings $7.5M (-20%); diluted EPS $0.41 vs $0.49.
USANA Q4 net loss $1.8M; core customers down 15%; FY2026 guidance flat to 8% growth
Q4 net loss $1.8M vs profit $4.5M YoY; adjusted diluted EPS $0.60 (down 6% from $0.64).
USANA sets CEO Guest compensation at $850K base, $1.7M RSU; Brown gets $1.5M severance
Jim Brown transitions to strategic advisor through Dec 31, 2026; receives $825K salary, eligible for 2025 bonus, benefits.
USANA prelim FY2025 sales ~$925M (beat guidance); FY2026 guidance $925M-$1B
Preliminary FY2025 net sales of ~$925M, above prior guidance of ~$920M.
USANA CEO Jim Brown steps down; Kevin Guest returns as CEO effective immediately
Jim Brown stepped down as CEO and President after 19 years; will remain in advisory role.
USANA Q3 net loss of $6.5M; lowers FY25 EPS guidance to $0.78 from $1.50-$2.20
Net sales $214M (+7% YoY) but net loss -$6.5M vs +$10.6M prior year; adj. diluted EPS -$0.15.
Q3 net sales $214M (up from $200M YoY) but operating earnings fall to $1.2M from $15.6M.
USANA Q2: net sales +11% to $236M, net earnings -7%; FY guidance reiterated
Net sales $236M (+11% YoY); net earnings $9.7M (-7% YoY); diluted EPS $0.52 (-4% YoY).
USANA enters $75M revolving credit facility with Bank of America, $200M accordion option
New $75M revolver replaces prior agreement; includes $200M accordion feature subject to conditions.
USANA shareholders approve 2025 Equity Incentive Plan at annual meeting
All eight director nominees elected, including Kevin G. Guest and Xia Ding.
USANA Q1 net sales up 10% to $250M; EPS down 43% to $0.49; reiterates FY outlook
Net sales $250M (+10% YoY); net earnings $9.4M (-43%); diluted EPS $0.49 vs $0.86.
USANA acquired controlling interest in Hiya on Dec 23, 2024; audited financials of Hiya now filed.
USANA Q4 net sales -3% to $214M; net earnings -73% to $4.5M; FY2025 guidance includes Hiya
Q4 net sales $214M (-3% YoY); net earnings $4.5M (-73%); diluted EPS $0.23 (-74%).
USANA acquires 78.8% stake in Hiya Health for $205M; Hiya had $103M sales, $22M adjusted EBITDA LTM
Acquired 78.8% controlling stake in Hiya Health for $205M cash; closed Dec 23, 2024.
USANA Q3 net sales $200M (-6% YoY); cuts FY2024 EPS guidance to $2.45
Q3 diluted EPS $0.56 vs $0.59 YoY; net sales down 6% to $200M.
USANA Q2 net sales $213M (-11% YoY), EPS $0.54 (-39%); cuts FY2024 guidance
Diluted EPS $0.54 vs. $0.89 in Q2 2023; net sales $213M down 11% YoY to $238M.
USANA shareholders re-elect eight board members, ratify KPMG, approve say-on-pay at annual meeting
All eight director nominees elected; vote totals ranged from 15.9M (Gilbert Fuller) to 16.86M (Kevin Guest) shares for.
USANA Q1 net sales $228M (-8% YoY), EPS $0.86, reaffirms FY2024 guidance
Net sales $228M (-8% YoY, -5% constant currency); diluted EPS $0.86 (-9% YoY).
USANA Q4 net sales $221M, EPS $0.87; FY2023 sales -8%; FY2024 guidance $850-920M
Q4 net sales $221M (-3% YoY, +4% seq); diluted EPS $0.87 (+32% YoY).
USANA Q3 net sales $213M, EPS $0.59; narrows FY 2023 guidance
Q3 net sales $213M (-9% YoY); diluted EPS $0.59 (-24% YoY).
USANA Q2 net sales $238M (-10% YoY), EPS $0.89; FY2023 guidance raised at low end
Q2 net sales $238M, down 10% YoY; diluted EPS $0.89 vs $1.00.
USANA CEO-to-be Jim Brown gets $800K base salary; Kevin Guest base cut to $750K as Executive Chair
Jim Brown's annual base salary as CEO increases from $627K to $800K effective July 1, 2023.
Approximately 89% of outstanding shares represented at May 10, 2023 annual meeting.
USANA Health Sciences to enter India in Q3 2023, first new market in 5 years
Expansion into India expected near end of Q3 2023; first new market in five years.
USANA Q1 net sales $248M, EPS $0.95; raises FY23 guidance low end
Net sales $248M, +9% sequentially but -9% YoY; diluted EPS $0.95 (+44% sequentially, -17% YoY).
USANA announces CEO transition: Jim Brown to succeed Kevin Guest as CEO effective July 1, 2023
Kevin Guest will transition to Executive Chairman; Jim Brown named CEO effective July 1, 2023.
USANA Q4 net sales $228M (-15% YoY), EPS $0.66 (-36%); FY2023 guidance reiterated
Q4 net sales $228M, down 15% YoY; diluted EPS $0.66, down 36% YoY.
Preliminary FY2022 net sales ~$995M, diluted EPS ~$3.65, above prior guidance of $955-975M and $3.15-$3.40.
USANA Q3 sales $233M (-15% YoY), EPS $0.78; slashes FY2022 guidance
Net sales $233M, down 15% YoY ($274M); diluted EPS $0.78 vs $1.36, down 43%.
USANA reappoints J. Scott Nixon as independent director effective July 25, 2022
Board expands to eight members; seven are independent.
USANA Q2 net sales $264M (-21% YoY), EPS $1.00 (-47%); FY2022 outlook reiterated
Net sales $264M (-21% YoY, -18% constant currency); diluted EPS $1.00 vs $1.87 prior year.
USANA preliminary Q2 net sales ~$265M (down 21% YoY); cuts FY2022 guidance sharply
Preliminary Q2 net sales ~$265M vs $337M a year ago; EPS ~$1.05 vs $1.87.
Approximately 17.37M shares (91% of outstanding) represented at the May 9, 2022 Annual Meeting.
USANA Q1 net sales $273M (-11% YoY), EPS $1.15 (-21% YoY); cuts FY2022 guidance
Net sales $272.9M, down 11% YoY; diluted EPS $1.15, down 21% from $1.45.
USANA Q4 net sales $267M (-14% YoY), EPS $1.03; FY22 guidance $5.25-$6.00 EPS
Q4 net sales $267.3M (-14% YoY), diluted EPS $1.03 (-45% YoY); active customers 560K (-7% YoY).
USANA Q3 net sales $274.4M, EPS $1.36; reiterates FY2021 outlook
Net sales $274.4M (-8% YoY); diluted EPS $1.36 (-6% YoY).
USANA appoints Xia Ding to board of directors, effective Oct 11, 2021
Xia Ding appointed as independent director; initial term through 2022 annual meeting.
USANA pre-announces Q3 net sales $265-$270M (down ~10% YoY); cuts FY2021 guidance
Preliminary Q3 EPS $1.28-$1.33 vs $1.44 prior year; net sales $265-$270M vs $299M.
USANA adopts nonqualified deferred compensation plan for key employees and named executive officers
Compensation Committee approved Deferred Compensation Plan on July 26, 2021 for key employees including named executive officers.
USANA posts record Q2 sales of $336.8M (+30.1% YoY); EPS $1.87 (+41.7% YoY)
Q2 net sales $336.8M, +30.1% YoY; diluted EPS $1.87, +41.7% YoY; active customers 652K (+8.8%).
its Board of Directors (the “Board”) appointed Jim Brown as the Company’s Chief Executive Officer effective July 1, 2023
Mr. Brown will succeed Kevin Guest, who will transition to Executive Chairman of the Company on the Effective Date.
On February 13, 2023, USANA Health Sciences, Inc. (the “Company” or “USANA”) announced that its Board of Directors (the “Board”) has appointed Jim Brown as the Company’s Chief Executive Officer effective July 1, 2023
Mr. Brown will succeed Kevin Guest, who will transition to Executive Chairman of the Company on the Effective Date.
Effective as of July 25, 2022, the Board of Directors of USANA Health Sciences, Inc. (the “Company”) acted unanimously to appoint J. Scott Nixon, CPA as an additional director of the Company
Effective as of October 11, 2021, the Board of Directors of USANA Health Sciences, Inc. (the “Company”) acted unanimously to appoint Xia Ding as an additional director of the Company, for an initial term expiring at the Company’s 2022 Annual Meeting of Shareholders.
Max materiality 0.85 · Median 0.72 · Most common event earnings